[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.189.139. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
April 7, 2004

Cardiovascular Effects of Ephedra

Author Affiliations
 

Letters Section Editor: Stephen J. Lurie, MD, PhD, Senior Editor.

JAMA. 2004;291(13):1560. doi:10.1001/jama.291.13.1560-b

To the Editor: Dr McBride and colleagues1 suggested that ephedra might be responsible for prolongation of the QT interval, increased P-wave duration, and elevated systolic blood pressures noted with the use of Metabolife 356. The authors acknowledged that the multi-ingredient nature of this product precludes a definite statement regarding causation but argued that the findings were unlikely to be due to caffeine. They did not discuss the other components of the supplement.

First Page Preview View Large
First page PDF preview
First page PDF preview
×